CTOs on the Move

Aerovate Therapeutics

www.aerovatetx.com

 
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aerovate Therapeutics raised $72.6M on 08/06/2020

Similar Companies

TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Bayhill Therapeutics

Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verano Holdings

Verano™ Holdings is a national, vertically-integrated operator of licensed cannabis cultivation, manufacturing and retail facilities dedicated to improving lives by providing safe access to effective organic cannabis products that enhance health and wellness and by positively impacting the communities it serves.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.

Alveo Technologies

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo`s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.